FDA OK's Ranbaxy's Generic Adoxa
Posted on: Friday, 2 June 2006, 12:01 CDT
Ranbaxy Pharmaceuticals Inc. has received U.S. approval to make and sell a generic version of Adoxa, an antibiotic.
The Food and Drug Administration's Office of Generic Drugs has determined the Ranbaxy formulation to be bioequivalent and have the same therapeutic effect as Adoxa, RPI said Friday.
A unit of India's Ranbaxy Laboratories Ltd., RPI expects to sell doxycycline pills in various strengths to treat respiratory tract and urinary tract infections, skin and skin structure infections and severe acne.
Adoxa is sold by Bioglan Pharmaceutical Co.
Source: United Press International
Related Articles
- Ranbaxy Wins FDA Approval for Generic Anti-Infective
- Ranbaxy Receives Approval To Market Doxycycline Tablets
- Ranbaxy Receives Final Approval To Market Benazepril Hydrochloride + HCTZ Tablets
- Ranbaxy Opens Third State-of-the-Art R&D Facility New Facility to Focus on NCE Discovery Research
- Ranbaxy Expects Boost in Revenue
- Ranbaxy Gains Tentative Approval to Market Additional Strengths of Glimepiride Tablets
- Ranbaxy Receives Tentative Approval for Zidovudine Tablets As Part of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Initiative
- Ranbaxy Gains Approval To Market Metformin XL Tablets, 750 Mg
- Ranbaxy Receives Final Approval for Clarithromycin XL 1000 Mg Tablet
Rating: 2.8 / 5 (4 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds